Pharming Group N.V.(PHAR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAR Pharming Group N.V.

Market Closed 12-12 16:00:00 EST

17.98

+0.25

+1.41%

盘后17.98

+0.000.00%

16:10 EST

High18.12	Low17.18	Vol58.79K
Open17.29	D1 Closing17.73	Amplitude5.30%
Mkt Cap1.23B	Tradable Cap1.21B	Total Shares68.51M
T/O1.04M	T/O Rate0.09%	Tradable Shares67.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PHAR","market":"US","secType":"STK","nameCN":"Pharming Group N.V.","latestPrice":17.98,"timestamp":1765573200000,"preClose":17.73,"halted":0,"volume":58789,"hourTrading":{"tag":"盘后","latestPrice":17.98,"preClose":17.98,"latestTime":"16:10 EST","volume":2,"amount":35.96,"timestamp":1765573804085},"delay":0,"floatShares":67071361,"shares":68514761,"eps":0.00218,"marketStatus":"Market Closed","change":0.25,"latestTime":"12-12 16:00:00 EST","open":17.29,"high":18.12,"low":17.18,"amount":1043204.0936,"amplitude":0.053017,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.00218,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":10,"listingDate":1608699600000,"exchange":"NASDAQ","adjPreClose":17.73,"preHourTrading":{"tag":"盘前","latestPrice":17.49,"preClose":17.66,"latestTime":"08:00 EST","volume":2,"amount":34.989998,"timestamp":1765544401142},"postHourTrading":{"tag":"盘后","latestPrice":17.98,"preClose":17.98,"latestTime":"16:10 EST","volume":2,"amount":35.96,"timestamp":1765573804085},"volumeRatio":3.296715032833533},"requestUrl":"/m/hq/s/PHAR","defaultTab":"news","newsList":[{"id":"1170588331","title":"Stock Track | Pharming Group N.V. Soars 8.93% on Strong Q3 Results and Raised FY25 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1170588331","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170588331?lang=en_us&edition=fundamental","pubTime":"2025-11-13 00:42","pubTimestamp":1762965738,"startTime":"0","endTime":"0","summary":"Shares of Pharming Group N.V. (PHAR) experienced a significant surge during Wednesday's trading session, soaring 8.93% in response to the company's impressive third-quarter financial results and...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAR"],"gpt_icon":0},{"id":"2583305437","title":"Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2583305437","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583305437?lang=en_us&edition=fundamental","pubTime":"2025-11-13 00:19","pubTimestamp":1762964340,"startTime":"0","endTime":"0","summary":"U.S. stocks were mixed, with the Dow Jones index gaining more than 300 points on Wednesday.Shares of Pharming Group N.V.  rose sharply during Wednesday's session after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.Pharming Group shares jumped 5.9% to $17.17 on Wednesday.Here are some other big stocks recording gains in today’s session.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/12/Section-Of-A-Financial-Newspaper-Titled-_2.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/12/Section-Of-A-Financial-Newspaper-Titled-_2.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/11/48809357/pharming-group-posts-upbeat-q3-results-joins-on-holding-bigbear-ai-holdings-and-other-big-stocks-moving-higher-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/11/48809357/pharming-group-posts-upbeat-q3-results-joins-on-holding-bigbear-ai-holdings-and-other-big-stocks-moving-higher-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4587","PHAR","BK4139","BK4134"],"gpt_icon":1},{"id":"2581188720","title":"H.C. Wainwright Remains a Buy on Pharming Group (PHAR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581188720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581188720?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:17","pubTimestamp":1762445858,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Pharming Group, with a price target of $37.00. Pantgin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-pharming-group-phar-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-pharming-group-phar-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PHAR"],"gpt_icon":0},{"id":"1129475046","title":"Stock Track | Pharming Group Soars 20.11% on Stellar Q3 Results and Raised 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1129475046","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129475046?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:41","pubTimestamp":1762440077,"startTime":"0","endTime":"0","summary":"Pharming Group N.V. (NASDAQ: PHAR) shares surged 20.11% in pre-market trading on Thursday, following the release of its impressive third-quarter 2025 financial results. The Dutch biopharmaceutical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAR"],"gpt_icon":0},{"id":"1187102986","title":"Stock Track | Pharming Group Soars 16.77% Pre-Market on Strong Q3 Results, Raised Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1187102986","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187102986?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:02","pubTimestamp":1762434149,"startTime":"0","endTime":"0","summary":"Pharming Group N.V. (NASDAQ: PHAR) shares surged 16.77% in pre-market trading on Thursday following the release of its impressive third-quarter 2025 financial results. The Dutch biopharmaceutical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAR"],"gpt_icon":0},{"id":"2581539150","title":"Pharming Group NV reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2581539150","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581539150?lang=en_us&edition=fundamental","pubTime":"2025-11-06 15:01","pubTimestamp":1762412465,"startTime":"0","endTime":"0","summary":"Pharming Group NV reports results for the quarter ended September 30 - Earnings SummaryPharming Group NV PHAR.OQ reported quarterly adjusted earnings of 1 cent per share for the quarter ended Septembe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL8N3WI0JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAR","BK4139"],"gpt_icon":0},{"id":"2581053502","title":"Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow","url":"https://stock-news.laohu8.com/highlight/detail?id=2581053502","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581053502?lang=en_us&edition=fundamental","pubTime":"2025-11-06 14:00","pubTimestamp":1762408800,"startTime":"0","endTime":"0","summary":"Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/06/3182172/0/en/Pharming-Group-reports-third-quarter-2025-financial-results-with-significant-growth-in-revenue-profitability-and-cash-flow.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823414551.USD","LU2357125470.USD","PHAR","LU2249611893.SGD","BK4139","LU0823414478.USD","CCO","LU2294711713.HKD","BK4009","LU2506951792.HKD"],"gpt_icon":0},{"id":"2580206645","title":"Pharming Group NV  expected to post breakeven results a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580206645","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580206645?lang=en_us&edition=fundamental","pubTime":"2025-11-04 14:14","pubTimestamp":1762236860,"startTime":"0","endTime":"0","summary":"Pharming Group NV  expected to post breakeven results a share - Earnings Preview Pharming Group NV PHAR.OQ, PHAR.O is expected to  show a rise in quarterly revenue when it reports  results on November","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG0C8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAR","BK4139"],"gpt_icon":0},{"id":"2573097766","title":"Pharming to Cut 20% of Non-Commercial, Non-Medical Headcount; Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2573097766","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573097766?lang=en_us&edition=fundamental","pubTime":"2025-10-07 00:14","pubTimestamp":1759767255,"startTime":"0","endTime":"0","summary":"Pharming Group  said Monday it is implementing a 20% net reduction in its non-commercial and non-medical headcount, primarily at the company's headquarters in the Netherlands, as part of its organizational restructuring.The restructuring is a part of a previously shared plan to lower general and administrative, or G&A, expenses, the company said.Pharming aims to cut total G&A costs by 15%, or $10 million per year, and expects to take a one-time restructuring charge of about $7 million in Q4 due to the staff reduction, according to the statement.Shares of the company fell 3.6% in recent trading Monday.Price: 15.42, Change: -0.58, Percent Change: -3.62","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHAR","BK4139"],"gpt_icon":0},{"id":"2573609169","title":"Pharming announces 20% net reduction in non-commercial, non-medical headcount","url":"https://stock-news.laohu8.com/highlight/detail?id=2573609169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573609169?lang=en_us&edition=fundamental","pubTime":"2025-10-06 23:50","pubTimestamp":1759765838,"startTime":"0","endTime":"0","summary":"Pharming (PHAR) Group announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is alig...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pharming-announces-20-net-reduction-in-non-commercial-non-medical-headcount-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pharming-announces-20-net-reduction-in-non-commercial-non-medical-headcount-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAR","BK4139"],"gpt_icon":0},{"id":"2572534630","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Government Shutdown Impact Weighs on Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2572534630","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572534630?lang=en_us&edition=fundamental","pubTime":"2025-10-01 21:10","pubTimestamp":1759324251,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.3% lower in Wednesday's premarket activity as investors grow unea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"bfa5c4fd6721401a918513df6c1b1daf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VIS","IYH","FAS","QQQ","XLY","USO","XLI","SOXX","XLF",".IXIC","IYE","EEM","SPY.AU","IYW","IVV","RTH.AU","SPY","XLE","XLP","RTH","ISBC","UNG","IYK","PMR","XRT",".DJI","EETH","VHT.AU","BETH","PHAR","BITO","IPK","EQR","VHT","IGM","TS","XLK","FAZ","VDC","EXI","XSD","XLV","AIR.AU","IYJ","AIR","IBB"],"gpt_icon":1},{"id":"2572058724","title":"Pharming Gets FDA Priority Review for Infection-Causing Genetic Disorder Drug For Children Aged 4-11","url":"https://stock-news.laohu8.com/highlight/detail?id=2572058724","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572058724?lang=en_us&edition=fundamental","pubTime":"2025-10-01 17:53","pubTimestamp":1759312391,"startTime":"0","endTime":"0","summary":"Pharming Group  said Wednesday the US Food and Drug Administration accepted its supplemental new drug application for leniolisib to treat children ages four to 11 with APDS, a genetic disorder, and granted priority review with a Jan. 31, 2026, target decision date.If approved, leniolisib would be the first treatment indicated for APDS in patients under 12, the company said.The filing is backed by a phase 3 study showing 12-week improvements in lymphadenopathy and naive B cells, plus eight months of safety data, Pharming said.Leniolisib, marketed as Joenja in the US, is already approved for APDS in patients 12 and older, the company added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PHAR"],"gpt_icon":0},{"id":"2570838220","title":"European Equities Traded in the US as American Depositary Receipts Rising Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2570838220","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570838220?lang=en_us&edition=fundamental","pubTime":"2025-09-27 00:05","pubTimestamp":1758902722,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were rising late Friday morning, up 0.7% to 1,544.28 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by bank BBVA  and clinical-stage biopharmaceutical company Cellectis , which rose 2.4% and 1.8%, respectively.They were followed by bank Santander , which added 1.5%.The decliners from continental Europe were led by biotech Evaxion  and biopharmaceutical company Pharming , which fell nearly 9% and past 6%, respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company Adaptimmune Therapeutics  and cell therapy company Autolus Therapeutics , which rose 22% and 3.7%, respectively.The decliners from the UK and Ireland were led by oncology biotech company Akari Therapeutics  and clinical diagnostic company Trinity Biotech , which lost 9% and 3.5%, respectively.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SAN","BK7142","BK4521","ADAP","AUTL","SAN.AU","BK4007","AFG","TRIB","BK4107","PHAR","BK4207","AKTX","BBVA","EVAX","BK4117","BK4139","BK4082","CLLS"],"gpt_icon":0},{"id":"2564718308","title":"Pharming Group Names Kenneth Lynard Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2564718308","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564718308?lang=en_us&edition=fundamental","pubTime":"2025-09-02 15:24","pubTimestamp":1756797842,"startTime":"0","endTime":"0","summary":"Pharming Group NV (PHAR) said Tuesday it has appointed Kenneth Lynard as chief financial officer, effective Oct. 1.Lynard most recently served as CFO of Schoeller Allibert and Zentiva, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHAR","BK4139"],"gpt_icon":0},{"id":"2564783338","title":"Press Release: Pharming Group appoints Kenneth Lynard as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2564783338","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564783338?lang=en_us&edition=fundamental","pubTime":"2025-09-02 13:00","pubTimestamp":1756789200,"startTime":"0","endTime":"0","summary":"Leiden, the Netherlands, September 2, 2025: Pharming Group N.V.   today announced the appointment of Kenneth Lynard as Chief Financial Officer , effective October 1, 2025.Mr. Lynard is a seasoned finance executive with over 20 years of global leadership experience in the life sciences industry, recognized for driving financial and operational transformation across complex, multinational organizations. His appointment follows our strong first half 2025 financial results and marks an important step in strengthening our financial leadership as we continue to execute on our growth strategy.\"We are delighted to welcome Kenneth to Pharming at a pivotal stage in our growth. Kenneth brings broad finance leadership capabilities from both established industry leaders and dynamic growth-stage companies, and operational experience in both the U.S. and EU. His strong value creation mindset, shaped by experience with companies backed by leading private equity firms, will be extremely valuable as we ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAR","CFO","BK4139"],"gpt_icon":0},{"id":"2555834092","title":"European Equities Traded in the US as American Depositary Receipts Falling Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2555834092","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555834092?lang=en_us&edition=fundamental","pubTime":"2025-07-31 23:17","pubTimestamp":1753975059,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were declining on Thursday morning, down 1.1% to 1,447.92 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Argenx  and pharmaceutical company Pharming , which rose 13% and 9.2% respectively.They were followed by financial services company BBVA , which was adding 7.4%.The decliners from continental Europe were led by beverage giant Anheuser-Busch Inbev  and pharmaceutical and healthcare company Sanofi , which fell 11% and 7.6% respectively.They were followed by pharmaceutical company Novo Nordisk , which was shedding 3.4%.From the UK and Ireland, the gainers were led by cryptocurrency miner Argo Blockchain  and pest control services company Rentokil Initial , which rose 13% and 9.4% respectively.The decliners from the UK and Ireland were led by semiconductor company Arm  and biopharmaceutical company Adaptimmune Therapeutics , which lost 12% and 9.8% respectively.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNY","LU0240878834.USD","RTO","IE00BZ1G4Q59.USD","ARGX","BK4585","LU1093756325.SGD","BK7104","LU0109394709.USD","BK4117","LU0348723411.USD","LU0154236417.USD","BK4588","BK4139","LU1093756168.USD","BK4599","IE00BMPRXQ63.HKD","BBVA","AFG","IE0009354923.USD","BUD","BUD.AU","BK4595","BK4023","BK4120","ARM.AU","BK4532","LU0205193047.USD","NVO.AU","BK4007","BK4543","BK4141","LU0240877869.USD","LU0320765992.SGD","LU0889565916.HKD","IE00BKVL7J92.USD","BK7119","LU0205194284.USD","BK4505","IE00BMPRXR70.SGD","IE00BMPRXN33.USD","BK4158","ADAP","PHAR","ARM","IE00BFXG1179.USD","ARBK","BK4107","BK4609"],"gpt_icon":1},{"id":"1183933705","title":"Stock Track | Pharming Group Soars 10.60% on Strong Q2 Results, Raised Guidance, and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1183933705","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183933705?lang=en_us&edition=fundamental","pubTime":"2025-07-31 21:33","pubTimestamp":1753968839,"startTime":"0","endTime":"0","summary":"Shares of Pharming Group N.V. (PHAR) surged 10.60% in pre-market trading on Thursday following the company's announcement of better-than-expected second-quarter results, raised full-year guidance,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAR"],"gpt_icon":0},{"id":"1153188425","title":"Stock Track | Pharming Group Soars 9.51% Pre-Market on Strong Q2 Results, Raised Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1153188425","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153188425?lang=en_us&edition=fundamental","pubTime":"2025-07-31 21:28","pubTimestamp":1753968537,"startTime":"0","endTime":"0","summary":"Shares of Pharming Group N.V. (PHAR) surged 9.51% in pre-market trading on Thursday following the company's announcement of better-than-expected second-quarter results and raised full-year guidance....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAR"],"gpt_icon":0},{"id":"1130180037","title":"Stock Track | Pharming Group Soars 9.51% Pre-Market on Strong Q2 Results and Raised 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1130180037","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130180037?lang=en_us&edition=fundamental","pubTime":"2025-07-31 21:28","pubTimestamp":1753968535,"startTime":"0","endTime":"0","summary":"Pharming Group N.V. (NASDAQ: PHAR) shares jumped 9.51% in pre-market trading on Thursday following the release of its second quarter and first half 2025 financial results, which surpassed analyst...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAR"],"gpt_icon":0},{"id":"2555100515","title":"Pharming Group NV reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2555100515","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555100515?lang=en_us&edition=fundamental","pubTime":"2025-07-31 14:00","pubTimestamp":1753941656,"startTime":"0","endTime":"0","summary":"Pharming Group NV reports results for the quarter ended June 30 - Earnings SummaryPharming Group NV PHAR.OQ reported quarterly adjusted earnings of 1 cent per share for the quarter ended June 30, high","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nL8N3TS0ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharming.com","stockEarnings":[{"period":"1week","weight":0.0734},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.2248},{"period":"6month","weight":0.6726},{"period":"1year","weight":0.9292},{"period":"ytd","weight":0.7864}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.028542},{"month":2,"riseRate":0,"avgChangeRate":-0.055174},{"month":3,"riseRate":0.4,"avgChangeRate":0.003746},{"month":4,"riseRate":0.4,"avgChangeRate":-0.065463},{"month":5,"riseRate":0.4,"avgChangeRate":0.040165},{"month":6,"riseRate":0.2,"avgChangeRate":-0.028823},{"month":7,"riseRate":0.6,"avgChangeRate":0.005182},{"month":8,"riseRate":0.4,"avgChangeRate":0.151843},{"month":9,"riseRate":0.2,"avgChangeRate":-0.071072},{"month":10,"riseRate":0.4,"avgChangeRate":-0.008815},{"month":11,"riseRate":0.4,"avgChangeRate":0.062772},{"month":12,"riseRate":0.6,"avgChangeRate":0.076719}],"exchange":"NASDAQ","name":"Pharming Group N.V.","nameEN":"Pharming Group N.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharming Group N.V.(PHAR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharming Group N.V.(PHAR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharming Group N.V.,PHAR,Pharming Group N.V.股票,Pharming Group N.V.股票老虎,Pharming Group N.V.股票老虎国际,Pharming Group N.V.行情,Pharming Group N.V.股票行情,Pharming Group N.V.股价,Pharming Group N.V.股市,Pharming Group N.V.股票价格,Pharming Group N.V.股票交易,Pharming Group N.V.股票购买,Pharming Group N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharming Group N.V.(PHAR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharming Group N.V.(PHAR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction